

25th June, 2026

- | | |
|--|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Proceedings of the 90th Annual General Meeting ('AGM') of the Company

Dear Sir/Madam,

We hereby inform that the 90th AGM of the Company was held on Thursday, 25th June, 2026 at 2.00 p.m. IST through video conferencing.

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing the following:

1. Speech by Dr Y K Hamied – Chairman
2. Presentation by Mr Achin Gupta – Managing Director and Global Chief Executive Officer
3. Proceedings of the AGM

Kindly take the above on record.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Simona Dsouza

Ninetieth Annual General Meeting Speech

Address by Dr Y K Hamied, Chairman, Cipla Limited on 25th June 2026

Dear Shareholders,

Welcome to the 90th Annual General Meeting of your Company.

We concluded another eventful year at Cipla, completing 90 years since Dr K A Hamied, our Founder, started the Company in 1935. Reflecting on this journey, one is reminded of our Founder's enduring belief that scientific progress must essentially serve society and humanity. This has guided Cipla through many decades of change and continues to define our approach to *'Caring for Life'*.

My own association with Cipla started in 1960 and spans seven decades. It has been a privilege to witness Cipla's growth and development, from a Company built on limited indigenous capability into a global organisation serving patients across the world. Our direction has always remained clear, to expand access to affordable medicines, strengthen R&D and scientific capability, address healthcare needs in a responsible and meaningful manner, and ensure that none should be denied medication. During the last financial year, Cipla's performance has maintained our position as a leading Indian pharma company.

We have a presence across a number of key markets and therapeutic areas. Our manufacturing and marketing capabilities reflect our position as a trusted and reliable partner. This, over the years, has been achieved through a consistent emphasis on maintaining excellent quality, improving scientific innovation and manufacturing strength.

Success is not the destination that one reaches. Success is the quality of the journey. The overall achievement of a company cannot be measured by monetary gain but by the capacity and capability to contribute towards the moral and social obligations of society. For the last 90 years, Cipla has focused on making medicines accessible, particularly to those in need, especially in India and Africa. An example of this was Cipla's pioneering response to the HIV/AIDS crisis in Africa during the early part of this century. We believe that our initiative resulted in saving millions of lives. Our efforts are ongoing to control diseases such as this, malaria, TB and parasitic infections.

This year, our Cipla Palliative Care Hospital in Pune will complete 29 years. It is the first centre of its kind in India and perhaps anywhere in the world. It portrays Cipla's philosophy and reflects our ongoing commitment to care beyond treatment. Over the years, this centre has provided comfort, relief, dignity, and support to thousands of patients and their families. We are gradually expanding this support system which will benefit palliative care services throughout India.

We celebrated Cipla's 90-year journey during the year. Cipla launched a comic book for children, which covers the Cipla Story that shows our value to the younger generation. The Government of India also recognised Cipla's contribution to public health by issuing a special commemorative stamp to mark our 90th year. Apart from this, Cipla introduced a virtual tour of its journey on our website (virtualtour.cipla.com) whereby a wide audience can participate in our history and legacy. This will continue to guide and inspire future generations.

Looking ahead, there is a clear responsibility that we must follow. Healthcare needs to evolve on a continuous basis, and access remains a major issue across many parts of the world, which we have to tackle. Cipla will always continue to respond with focus and discipline and remain true to its purpose of providing access to affordable quality medicines. We are delivering a meaningful impact in the world of medicine guided by scientific progress and catering to patient needs.

One of the strengths of Cipla continues to be its people. Today, with a global workforce of around 31,000, there is a shared sense of purpose that binds us all together. It involves commitment, integrity, honesty and belief which uphold Cipla's values that will sustain us in the future.

We would like to thank two Board Members who have completed their tenure, Mr Vohra, and Mr Stewart, for their contribution and wish them the very best in the years ahead. I am pleased to welcome Mr P R Ramesh our Lead Independent Director as Vice-Chairman of our Company. His experience and association with the Board have been invaluable and he will continue to assist Cipla as we have entered the next decade. We also welcome Mr Achin Gupta as our Managing Director and Global CEO. Apart from this, my sincere thanks to the medical profession, all our local and international partners, as also those who work along with us to ensure patients' needs are met with care. Above all, I would like to thank you, our shareholders, for your continued trust, support and confidence in Cipla.

We are moving forward towards our century in 2035. This milestone will be an ongoing responsibility, which we have to face with integrity and commitment to continue our progress in Caring for Life. We will maintain the legacy of our mission into the next century. We are confident that Cipla will uphold its values and continue to contribute meaningfully to improving the quality of life of our fellow men in the years ahead.

Thank you.



Cipla House

Cipla

90 YEARS 

CARING FOR LIFE

Annual General Meeting

MD & GCEO's Address



Achin Gupta

June 2026

Highest-ever Yearly Revenue Despite Multiple Headwinds

	Revenue	EBITDA	PAT
FY26	INR 28,163 Cr	INR 5,925 Cr (21.0% Margin)	INR 3,879 Cr (13.8% Margin)


Business Performance Snapshot

	One India	North America	One Africa	Emerging Markets & Europe
FY26	INR 12,680 Cr  9% (YoY)	\$ 780 Mn	\$ 483 Mn  7% (YoY)	\$ 405 Mn
	<i>Delivered double-digit growth across 3 segments in Q4 FY26</i>	<i>Received approval for the first AB-rated gVentolin with CGT</i>	<i>SA private growing at a market¹ growth multiple of 1.4x</i>	<i>Crossed \$ 400 Mn benchmark</i>


Building scale with Financial Discipline

Strong \$1Bn+ Net Cash position

Revenue¹



Total Cash²



614 Cr.

Total Debt³



7%.

R&D⁴ Expense
% of revenue

Strengthening Leadership Across Key Markets



India

1st
 No. 1 pharma company in India in volume terms¹



South Africa

2nd
 Largest pharma company in prescription market²



North America

3rd
 Largest by prescription for generic inhalation products in the US³



Emerging Markets

2nd
 Largest Indian exporter to emerging markets⁴



Patient Centric Product Innovation

- CGT portfolio of **Ciplostem, Regenacip and Xtiktr** is gaining traction in India
- Launch of innovative product portfolio - Voltido Trio, Afrezza (inhaled insulin), Zemdri (Plazomycin)



Manufacturing footprint

- Strong manufacturing presence across India, US, South Africa, China amongst other countries
- Expanded DPI capabilities in US & MDI in US & Morocco



Key Partnerships

- Secured rights from **Eli Lilly** to distribute and promote **Yurpeak®** in India
- Exclusive marketing and distribution rights for **Pfizer key brands** (Corex, Dolonex, Neksium, Dalacin C)
- 100% stake acquisition of Inzpera, adding a differentiated pediatrics & wellness portfolio

Sustaining Quality as Foundation for Growth

46 Regulatory inspections completed in FY26 by

USFDA

WHO - Geneva

ANVISA - Brazil

PMDA

EMA

and other regulatory bodies

No critical observations during these inspections

USFDA
Inspections

Bommasandra
Received VAI

May'25

Invagen
EIR Awaited from FDA

Feb'26

Embedding Sustainability into Core Operations



Achieved **82%**¹ reduction in scope 1² & scope 2 GHG emission compared to FY2019-2020

Achieved 2.6 times **water positive**

All Cipla India Manufacturing operations are **ZWTL**³ **re-certified**
2 warehouses ZWTL certified

84% **renewable electricity** usage

Zero Fatality in Manufacturing Operations

Achieved full compliance with the safe discharge targets established by **AMR Industry Alliance**

Achievements and Recognition

Cipla has been included in the 2026 Dow Jones **Best in Class** World Index



S&P Global Corporate Sustainability Assessment ("DJSI")

81



Ranked by Business World as **Top Sustainable Companies**

- 5th in Healthcare and Pharma sector and
- 46th among the top 60 companies, in India

Long Term Goal

Committed to achieve **Net zero by 2050**

Cipla Foundation: Advancing Access to Care

Health - Palliative Care

65,900+ patients supported through **37 partners** across **20 states**


Directly supported **1000+** patients & their families through the **Cipla Palliative Care & Training Centre**, Pune

5,000+ patients referred to palliative care services through the **Saath-Saath Helpline** since 2021



Health - Respiratory

MOU signed for the establishment of the **Cipla Foundation Centre for Pulmonary Medicine** at the Tata IISc Medical School, Bengaluru



2,55,200+
Lives touched

Environmental Sustainability

Through **watershed projects** in 5 states –

- 3.8 million KL of rainwater harvested and Cipla achieved **2.6 times water positivity**
- **28,000+** people and **100+** villages supported
- **2000+** renewable energy solutions installed till March '26

Launched a flagship bio-diversity initiative: **Eco-restoration of Ujjani Wetland** with Bombay Natural History Society (BNHS)



Recognized for Excellence: Accolades

Gold Shield in **Large Manufacturing and Trading Sector category** at the ICAI Awards for Excellence in Financial Reporting 2024-25



Leadership Category in **Indian Corporate Governance Scorecard 2025** by Institutional Investor Advisory Services

Certified as **Great Place to Work for eighth year in a row** (January 2026 to January 2027)



Awarded with **Excellence in R&D** at CPHI India Pharma Awards 2025

Recognition of **Cipla's Global Supply Chain** at the Institute of Supply Chain Management (ISCM) Pharma



'**Breathefree**' campaign recognized in **Top Healthcare Awareness Campaign** category at the 16th Elets Healthcare Innovation Awards 2025

AmbitionBox Employee Choice Awards 2025 - **Top Rated Large Company** and **Top Rated Pharma Company**



Goa sites awarded **Gold for National Award for Manufacturing Competitiveness** for FY 2024-25 by International Research Institute for Manufacturing

Looking ahead: Building for the Future

One India

Achieve #2 position in IPM, driven by Respiratory & Chronic franchise

North America

To be #1 in Respi Rx market (MDI, DPI, Respules)
 Build a differentiated pipeline & 505(b)(2) opportunities

EMEU

Build a 4th deep market

Build meaningful presence in deep markets

One Africa

Attain #1 position in the SA private market



Manufacturing

Strengthen Platforms, Expand Capacity



Supply Chain

Optimize Networks, AI-Driven Sourcing



Quality

Strong Compliance



IT

Data-Driven Excellence

01

Leadership in Home markets

Cipla's Strategic Vision 2031

Operational Excellence & Continuous Improvement

Patient-Centric Product Innovation

03

Robust pipeline to drive growth

- **North America:** Healthy pipeline of Respi. assets, Peptides, Oligo & 505(b)(2) Differentiated Products
- **India:** Strong pipeline for First-to-Launch Products
- **EMEU & One Africa:** Robust portfolio leveraging NA pipeline

02



Unlock value from inroads into novel modalities such as

- ✓ CAR-T mRNA Stem-cells

Dial-up our Innovation engine in key therapy areas:

India & EMs

Global

Oncology

Infectious diseases

Priority therapy areas

Respiratory

Immunology



Aim to become a substantial player in Biosimilars



Purpose as Our True North

Over 90 years, our purpose of
'Caring for Life'
has been the heartbeat of Cipla.

It shapes every **innovation** we
pioneer, every **partnership** we
forge and every **life** we touch.



A photograph of three children running across a green lawn in a park. The child on the left is a boy in a light blue patterned shirt and dark shorts. The child in the middle is a boy in a grey and blue baseball-style shirt and red shorts, smiling. The child on the right is a girl in a blue and white striped tank top and blue shorts. The background shows lush green trees. A semi-transparent hexagonal grid pattern is overlaid on the entire image.

Cipla

Thank You

Summary of proceedings of the 90th Annual General Meeting

The 90th Annual General Meeting ('AGM') of the members of Cipla Limited (the 'Company') was held on Thursday, 25th June, 2026, through Video Conferencing ('VC'). In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the webcast facility was also provided to the members. The AGM commenced at 2:00 p.m. IST and concluded at 4:48 p.m. IST (including time allowed for e-voting at the AGM).

Directors present:

- 1) Dr Y K Hamied – Non-Executive Chairman
- 2) Mr P R Ramesh – Vice-Chairman, Lead Independent Director and Chairman – Audit Committee
- 3) Mr Achin Gupta – Managing Director and Global Chief Executive Officer
- 4) Mr Abhijit Joshi – Non-Executive Director
- 5) Mr Adil Zainulbhai – Non-Executive Director
- 6) Dr Balram Bhargava – Independent Director and Chairman - Corporate Social Responsibility Committee
- 7) Mr Kamil Hamied - Non-Executive Director
- 8) Dr Mandar Vaidya – Independent Director and Chairman - Investment and Risk Management Committee and Stakeholders Relationship Committee
- 9) Ms Maya Hari - Independent Director and Chairperson – Nomination and Remuneration Committee
- 10) Ms Sharmila Paranjpe - Independent Director

In attendance:

- 1) Mr Ashish Adukia – Global Chief Financial Officer
- 2) Mr Rajendra Chopra – Company Secretary
- 3) Mr Adi Sethna – Representative of Walker Chandio & Co. LLP, Chartered Accountants, Statutory Auditors
- 4) Mr Avinash Bagul – Representative of BNP & Associates, Secretarial Auditors
- 5) Mr Ashish Thatte – Representative of M/s Joshi Apte & Associates, Cost Accountants, Cost Auditors
- 6) Ms Anshu Agarwal – Managing Partner, ANGC & Co. LLP, Practising Company Secretary, Scrutiniser for the purpose of remote e-voting and e-voting at the AGM
- 7) Ms Jas Sahib Singh Chadha – Representative of DNV Business Assurance India Private Limited, Assurance Provider for the Integrated Annual Report and the Business Responsibility and Sustainability Report

Members present: 92

Pursuant to Article 77 of Articles of Association of the Company, Dr Y K Hamied, Chairman presided over the meeting and Mr P R Ramesh, Vice Chairman, assisted in the conduct of the proceedings. The meeting was called to order. Mr P R Ramesh, Vice-Chairman, introduced the Directors, Management Team, Scrutinizer and representatives of the Statutory Auditors, Secretarial Auditors, Cost Auditors, and Assurance Provider participating through VC.

Mr Rajendra Chopra, Company Secretary, made the statutory announcements and *inter-alia* informed the members that:

- a) the meeting was being held through VC in accordance with the provisions of the Companies Act, 2013 and various circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI).
- b) the Integrated Annual Report containing the Financial Statements, Board's Report, Statutory Auditor's report and other reports along with the Notice of the meeting circulated to the members were taken as read.
- c) since there were no qualifications, observations, comments or remarks in the Statutory Auditor's and the Secretarial Auditor's reports for the year ended 31st March, 2026, the reports were taken as read.
- d) the e-voting facility commenced at 9:00 a.m. (IST) on Sunday, 21st June, 2026 and ended at 5:00 p.m. (IST) on Wednesday, 24th June, 2026. The voting rights were reckoned on the shares held as on the cut-off date i.e., Thursday, 18th June, 2026.
- e) e-voting facility during the AGM was made available for members who had not exercised their vote through e-voting facility and was open up to 30 minutes from the conclusion of the meeting.
- f) the statutory documents and reports as required to be placed at the AGM were open for inspection electronically.

Dr Y K Hamied, Chairman addressed the members and delivered his speech. Thereafter, Mr Achin Gupta, Managing Director and Global Chief Executive Officer ('MD & GCEO'), was invited to brief the members on the operations and performance of the Company.

The MD & GCEO made a brief presentation *inter-alia* covering the business performance, performance across key markets, quality, ESG, CSR initiatives, awards and accolades, and Cipla's strategic vision 2031.

With the permission of the Chairman and Vice-Chairman, the Company Secretary explained to the members the resolutions put forth for approval. He stated that since the meeting was held through VC and the resolutions provided in the Notice were being put to vote through e-voting, there would be no proposing and seconding of the resolutions.

The summary of the resolutions put up for members' approval was as under:

Sr. No.	Agenda Item	Type of Resolution
Ordinary Business		
1.	To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended 31 st March, 2026 and the reports of the Board of Directors and Statutory Auditor thereon.	Ordinary
2.	To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended 31 st March, 2026 and the report of the Statutory Auditor thereon.	Ordinary
3.	To declare dividend on equity shares.	Ordinary
4.	To re-appoint Mr Adil Zainulbhai as a director liable to retire by rotation	Ordinary
5.	To appoint M/s B S R & Co. LLP, Chartered Accountants as the Statutory Auditors of the Company and fix their remuneration.	Ordinary
Special Business		
6.	To ratify remuneration of M/s Joshi Apte & Associates, Cost Auditors, for the financial year ending 31 st March, 2027.	Ordinary

The Company Secretary then invited the members to express their views and ask questions. The members complimented the Board and management on the Company's performance, and asked questions on various matters including strategy, financial performance, product pipeline, ESG, AI, R&D, in-licensing deals, performance of partner products and impact of geopolitical issues. Mr Achin Gupta, Managing Director and Global Chief Executive Officer, Mr Ashish Adukia, Global Chief Financial Officer and Mr Rajendra Chopra, Company Secretary, suitably answered the questions asked.

The Vice-Chairman thanked the members for attending the 90th AGM of the Company and authorised the Company Secretary to conclude the meeting, receive the Scrutiniser's Report and announce the voting results.

Upon completion of the e-voting process, the Company Secretary declared the meeting as concluded.

As per the Scrutiniser's Report received, all the resolutions as set out in the Notice were passed by requisite majority.

Thanking you,

**Yours faithfully,
For Cipla Limited**

**Rajendra Chopra
Company Secretary**